Artificial organs and implants

In short

An artificial organ is an engineered device that replaces or assists the function of a failed natural organ, while an implant is any device placed wholly or partly inside the body and left there for an extended period. The field spans heart valves, stents, pacemakers, ventricular assist devices, oxygenators, cochlear implants, intraocular lenses, joint and dental implants, shunts and artificial pancreas systems — each a combination of a biomaterial, a mechanical or electrical function, and a surgical interface. In India these devices are regulated as drugs under the Medical Devices Rules, 2017 by CDSCO, tested against IS/ISO standards, and several are made locally (SCTIMST's Chitra valve, Meril and SMT stents, Pacetronix pacemakers, Aurolab intraocular lenses). The topic carries steady marks in biomedical engineering university exams and GATE BM (devices and instrumentation), and is a staple of technical rounds at Meril, SMT, Translumina, Philips, GE Healthcare, Siemens Healthineers, Medtronic/Abbott India, SCTIMST and Appasamy.

Explained

What counts as an artificial organ or an implant, and how they are classified

• Replacement devices take over function completely (mechanical heart valve, intraocular lens, total hip); assist devices share the load (LVAD, intra-aortic balloon pump); extracorporeal organs work outside the body for hours (membrane oxygenator, cell-based liver support).
• By duration of tissue contact (ISO 10993-1 scheme): limited (≤24 h), prolonged (>24 h to 30 days), long-term (>30 days). Implant risk rises with duration and with blood contact.
• By activity: *passive/structural* (valve, stent, hip stem, IOL) versus *active implantable* (pacemaker, ICD, cochlear implant, neurostimulator) which contain their own energy source and are governed by the IS/ISO 14708 series.
• By location: blood-contacting (valves, stents, VADs, grafts), soft-tissue (shunts, meshes, breast implants), hard-tissue (orthopaedic, dental, cranial plates), sensory/neural (cochlear, retinal, DBS).
• CDSCO risk class under the Medical Devices Rules, 2017: A (low), B (low–moderate), C (moderate–high), D (high). Almost all long-term implants are Class C or D; heart valves, stents and pacemakers are Class D.
• An implant's design is always a compromise between function (haemodynamics, load transfer, stimulation), durability (fatigue, wear, corrosion) and host response (thrombosis, infection, fibrosis) — no single material or geometry optimises all three.

Cardiovascular organs and implants

• Prosthetic heart valves — mechanical: caged-ball (Starr-Edwards, historical), tilting-disc (Björk-Shiley, Chitra), and the modern bileaflet (St. Jude type) in pyrolytic carbon with a titanium or cobalt-chrome housing and a PET/PTFE sewing ring. Essentially unlimited structural life but need lifelong anticoagulation (warfarin, INR target typically 2.5–3.5 depending on valve and position).
• Prosthetic heart valves — biological (bioprosthetic): glutaraldehyde-fixed bovine pericardium or porcine aortic valve on a stented or stentless frame; central, near-physiological flow and little or no anticoagulation, but structural valve degeneration by calcification limits life to roughly 10–20 years, faster in young patients and in renal failure.
• Transcatheter valves (TAVI/TAVR): a bioprosthetic leaflet set on a self-expanding nitinol or balloon-expandable frame, delivered through the femoral artery; India's Meril Myval is an example. Key failure modes are paravalvular leak and conduction block.
• Indian milestone: the TTK Chitra tilting-disc valve developed at SCTIMST, Thiruvananthapuram, made prosthetic valve replacement affordable (a fraction of imported valve cost).
• Stents: bare-metal (316L stainless steel, cobalt-chrome), drug-eluting (sirolimus/everolimus/paclitaxel in a polymer coating that suppresses neointimal hyperplasia), and bioresorbable scaffolds (PLLA or magnesium). Design metrics: radial strength, recoil, foreshortening, crossing profile, strut thickness (thinner struts reduce restenosis), fatigue life under pulsatile loading.
• Pacemakers: sense intrinsic cardiac electrical activity and pace when it is absent. NBG code letters: chamber paced, chamber sensed, response (I inhibited, T triggered, D dual), rate modulation (R). VVI paces and senses the ventricle and is inhibited by an intrinsic beat; DDD is dual-chamber, dual-sensing, dual-response; AAI is atrial. Components: lithium-iodine cell, hybrid circuit, hermetic titanium can, feedthroughs, and endocardial leads (active fixation screw or passive tines), increasingly leadless intracardiac capsules.
• ICD (implantable cardioverter-defibrillator): adds tachycardia detection and high-voltage shock therapy (capacitor charged to several hundred volts, 20–40 J delivered); CRT paces both ventricles to resynchronise a failing heart.
• Ventricular assist devices and artificial hearts: modern continuous-flow rotary pumps (axial or centrifugal, magnetically or hydrodynamically levitated impellers) replaced bulky pulsatile sacs; used as bridge-to-transplant, bridge-to-recovery or destination therapy. Problems: pump thrombosis, haemolysis, driveline infection, GI bleeding from acquired von Willebrand factor cleavage, and percutaneous power transfer. Total artificial hearts replace both ventricles. India's development effort includes the IIT Madras–led LVAD programme.
• Membrane oxygenator (artificial lung): hollow-fibre polymethylpentene or polypropylene bundle; gas flows inside the fibres, blood outside; transfers O₂ in and CO₂ out with a heat exchanger for temperature control. Used in cardiopulmonary bypass (hours) and ECMO (days to weeks). Heparin or heparin-coated circuits control clotting; plasma leakage and condensate limit microporous membranes in long runs.
• Vascular grafts: ePTFE and knitted/woven Dacron work well at large diameter and high flow; small-diameter (<6 mm) synthetic grafts fail by thrombosis and anastomotic hyperplasia, which is why the saphenous vein and radial artery remain the bypass conduits of choice.

Sensory, neural and endocrine devices

• Cochlear implant: microphone → speech processor → RF transcutaneous link → implanted receiver-stimulator → electrode array (typically 12–24 contacts) in the scala tympani stimulating the spiral ganglion tonotopically. Needs a surviving auditory nerve; outcome depends strongly on age at implantation. In India, surgery and device are supported under the ADIP scheme of the Department of Empowerment of Persons with Disabilities for children of eligible families (ceiling of the order of ₹6 lakh; the scheme's norms are revised from time to time).
• Intraocular lens (IOL): replaces the cataractous lens — PMMA (rigid) or foldable hydrophobic/hydrophilic acrylic and silicone; monofocal, multifocal, toric and accommodating types. Power chosen from biometry using the SRK/SRK-II or modern optical formulae. Aurolab (Madurai) manufactures IOLs at a few hundred rupees, which underpins mass cataract surgery in India.
• Retinal prostheses and visual implants: epiretinal/subretinal microelectrode arrays convert camera images into pulse trains; still limited resolution and largely investigational.
• Neurostimulators: deep brain stimulation for Parkinson's disease and dystonia, spinal cord stimulators for chronic pain, vagus nerve stimulators for epilepsy, sacral stimulators for incontinence — all active implants with rechargeable or primary cells and programmable pulse width, amplitude and frequency.
• Artificial pancreas: continuous glucose monitor + control algorithm (PID or model-predictive) + insulin pump in a closed loop; implantable islet-encapsulation and fully implanted pumps remain research-stage.
• Other organ substitutes: implantable hydrocephalus shunts (differential-pressure or programmable valves draining CSF ventriculo-peritoneally; SCTIMST's Chitra shunt is an Indian example), artificial urinary sphincters, penile and middle-ear implants, bioartificial liver devices using hepatocyte cartridges plus adsorption (albumin dialysis), and implantable drug-delivery pumps.

Structural (hard-tissue) implants

• Total hip replacement: femoral stem (Ti-6Al-4V or CoCrMo), head (CoCrMo, alumina or zirconia-toughened ceramic), acetabular cup with UHMWPE liner (often highly cross-linked and vitamin-E stabilised); cemented (PMMA) or cementless with porous/HA coating relying on osseointegration.
• Bearing couples: metal-on-polyethylene (standard), ceramic-on-polyethylene (lower wear than metal-on-polyethylene), ceramic-on-ceramic (lowest wear, risk of squeaking and fracture), metal-on-metal (largely abandoned after metal-ion and pseudotumour problems).
• Failure modes: polyethylene wear debris → macrophage activation → periprosthetic osteolysis → aseptic loosening (the dominant long-term cause of revision), stress shielding from a stiff stem (bone resorbs where it is unloaded — Wolff's law), stem fatigue fracture, dislocation, and periprosthetic infection with biofilm.
• Knee, shoulder, spinal implants: condylar knee with a mobile or fixed polyethylene insert; pedicle screw-rod constructs and interbody cages for fusion; disc replacements for motion preservation.
• Fracture fixation (temporary implants): plates, screws, intramedullary nails, external fixators in stainless steel 316L or titanium alloy; magnesium and PLA/PLGA devices resorb and avoid removal surgery.
• Dental implants: commercially pure titanium or Ti-Zr root-form screw osseointegrated into the jaw, with abutment and crown; success needs primary stability, controlled drilling temperature, and no micromotion above roughly 100 µm during healing.

Common engineering requirements and failure modes

• Haemocompatibility: blood-contacting surfaces must not activate platelets, the coagulation cascade or complement; smooth, low-shear, wash-out-free geometry plus surface treatment (heparin, phosphorylcholine, carbon). Regions of stagnation or very high shear both cause trouble — stasis for thrombus, high shear for haemolysis and vWF damage.
• Durability: a heart valve sees ~37 million cycles a year, so durability testing is in hundreds of millions of accelerated cycles; hip implants are tested for several million gait cycles; leads for flexion fatigue.
• Infection: implant surfaces are prone to biofilm, which resists antibiotics; prevention is sterile processing (EO, gamma/E-beam, steam as applicable), antibiotic prophylaxis, antimicrobial coatings, and short operative time.
• Power and telemetry: primary lithium cells for pacemakers, Li-ion with inductive recharging for neurostimulators and some VADs; bidirectional telemetry for programming and remote monitoring; cybersecurity of the wireless link is now a design requirement.
• MR conditional labelling: metallic implants cause heating, torque, displacement and image artefact; devices are labelled MR safe/conditional/unsafe with stated field, gradient and SAR limits.
• Device-specific risks: valve calcification and pannus, stent restenosis and late stent thrombosis, lead dislodgement and insulation breach, shunt over-drainage and obstruction, IOL glistening and posterior capsular opacification.

Indian regulation, standards and practice

• Statute: medical devices are regulated as *drugs* under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017; since 1 October 2022 all medical devices are notified, so every implant needs registration/licence. CDSCO (Central Licensing Authority) handles Class C and D; State Licensing Authorities handle Class A and B.
• Licence forms: manufacture — MD-5/MD-6 (Class A/B), MD-7/MD-9 (Class C/D); import — MD-14/MD-15; clinical investigation of an investigational device — MD-22/MD-23 under Chapter VII of the Rules. Applications go through the CDSCO online portal; Class C/D manufacture requires an ISO 13485 quality system and conformity to the Essential Principles in the First Schedule.
• Standards commonly cited: IS/ISO 10993 series (biological evaluation), IS/ISO 5840 (cardiovascular implants — heart valve substitutes), ISO 25539 (endovascular devices/stents), IS/ISO 14708 series (active implantable medical devices, including pacemakers and cochlear implants), ISO 7206 (hip-joint prostheses), ISO 14243 (knee wear), ISO 11135/11137/17665 (EO, radiation and moist-heat sterilisation), ISO 11607 (sterile packaging), ISO 14971 (risk management), IEC 60601 series for external electrical equipment. Where an old IS number has been withdrawn or renumbered, cite the standard by subject rather than a stale number.
• Price control: the NPPA has capped the retail price of coronary stents (bare-metal and drug-eluting) and of knee-implant systems since 2017; the ceilings are revised annually with WPI, so quote the current NPPA notification rather than a remembered figure.
• Other practice: adverse-event reporting under the Materiovigilance Programme of India (MvPI) coordinated by IPC, Ghaziabad; the Indian Pharmacopoeia 2026 (10th edition) is current for pharmacopoeial matters; hospital-side implant traceability under NABH accreditation; a national UDI framework has been in phased development, so state its status as evolving rather than as a settled mandate.

Key points

• Artificial organ - engineered device replacing or assisting failed organ function; implant - a device left in the body long-term.
• Mechanical valve - pyrolytic carbon bileaflet, lasts decades, needs lifelong warfarin.
• Bioprosthetic valve - tissue leaflets, little anticoagulation, fails by calcific degeneration in ~10-20 years.
• Valve choice rule of thumb - younger patients get mechanical (durability), older or anticoagulation-intolerant get tissue.
• Chitra valve - SCTIMST tilting-disc valve, the Indian indigenisation benchmark.
• Drug-eluting stent - antiproliferative drug in a polymer coating cuts in-stent restenosis versus bare metal.
• NBG pacemaker code - position 1 paced, 2 sensed, 3 response (I/T/D), 4 rate response; DDD = dual chamber dual sensing dual response.
• ICD - adds tachyarrhythmia detection and a 20-40 J shock; CRT resynchronises the ventricles.
• Continuous-flow LVAD - rotary impeller pump; risks are thrombosis, haemolysis, driveline infection.
• Membrane oxygenator - hollow-fibre artificial lung; gas inside fibres, blood outside; CPB for hours, ECMO for days.
• Osseointegration - direct bone-to-implant bonding needed by dental and cementless orthopaedic implants.
• Aseptic loosening - wear-debris-driven osteolysis; the leading long-term cause of joint revision.
• Stress shielding - a stiff implant unloads bone, which then resorbs (Wolff's law).
• Cochlear implant - bypasses the damaged cochlear hair cells, stimulating the auditory nerve tonotopically through 12-24 electrodes.
• IOL - artificial lens after cataract extraction; India's mass cataract programme rests on low-cost local IOLs.
• Risk classes A-D under the Medical Devices Rules, 2017; implants are typically C or D, licensed by CDSCO.
• Haemocompatibility trade-off - stasis causes thrombus, excessive shear causes haemolysis; both must be designed out.
• Durability target - a valve must survive hundreds of millions of cycles; accelerated fatigue testing per ISO 5840 proves it.

Formulas and examples

Example 1 — effective orifice area of an aortic valve prosthesis. Q_rms = 250 mL/s, mean systolic Δp = 20 mmHg. √20 = 4.472; 51.6 × 4.472 = 230.8. EOA = 250 / 230.8 = 1.08 cm². A 23 mm prosthesis giving ~1.1 cm² with a 20 mmHg gradient is acceptable; below ~0.8 cm² it is behaving stenotically and patient-prosthesis mismatch must be considered.

Example 2 — pacemaker longevity. Battery 1.0 Ah; output 2.5 V, 0.4 ms pulse into a 500 Ω lead; rate 70 ppm; circuit quiescent drain 8 µA.

1. Pulse current = 2.5/500 = 5 mA.
2. Duty cycle = 0.4 ms × (70/60 pulses per s) = 0.4×10⁻³ × 1.1667 = 4.667×10⁻⁴.
3. Average pacing current = 5 mA × 4.667×10⁻⁴ = 2.33 µA.
4. Total drain = 2.33 + 8 = 10.33 µA.
5. Life = 1,000,000 µAh / 10.33 µA = 96,800 h ÷ 8,766 h/yr = ≈ 11.0 years (≈ 9.9 years if 10 % is held as reserve). Note the quiescent circuit, not the pacing output, dominates the drain at these settings.

Example 3 — polyethylene wear in a total hip. k = 1.0×10⁻⁶ mm³/(N·m), W = 2,500 N, 28 mm head, 1 million gait cycles a year, 20 mm sliding per cycle.

1. s = 1×10⁶ × 0.020 m = 20,000 m/yr.
2. V = 1.0×10⁻⁶ × 2,500 × 20,000 = 50 mm³/yr.
3. Projected area = (π/4) × 28² = 615.8 mm² → linear penetration = 50/615.8 = 0.081 mm/yr, matching the ~0.1 mm/yr seen clinically with conventional UHMWPE.
4. An 8 mm liner would take ~99 years to wear through — so the implant is limited not by liner thickness but by the biological reaction to ~50 mm³ of debris a year, which is why cross-linked polyethylene (k an order lower) extended implant survival.

Example 4 — oxygenator gas transfer. Blood flow 4.0 L/min, Hb 10 g/dL, inlet saturation 70 %, outlet 100 %.

1. O₂ carried per litre at full saturation = 1.34 × 100 g/L = 134 mL/L.
2. Δ saturation 0.30 → 134 × 0.30 = 40.2 mL/L.
3. VO₂ = 4.0 × 40.2 = 161 mL/min (plus a small dissolved-O₂ contribution). This covers the ~160-250 mL/min resting demand of an adult, so flow or haematocrit must be raised for a larger patient.

Example 5 — haemolysis check on a blood pump. Δ free Hb = 0.10 g/L over a 6 h (360 min) loop test, circuit volume 0.45 L, Hct 30 %, Q = 5 L/min. NIH = 0.10 × 0.45 × (1 − 0.30) × 100 / (5 × 360) = (0.10 × 0.45 = 0.045; × 0.70 = 0.0315; × 100 = 3.15) / 1800 = 0.0018 g/100 L, well inside the commonly used acceptance band of < 0.01 g/100 L for a clinical pump.

Where it is used

• Cardiovascular device manufacture in India: Meril (Vadodara — stents, Myval transcatheter valve), Sahajanand Medical Technologies and Translumina (stents), TTK Healthcare and SCTIMST (Chitra valve), Pacetronix (Indore — pacemakers); roles in R&D, process validation, fatigue and flow-loop testing.
• Ophthalmic and ENT devices: Aurolab and Appasamy Associates (IOLs, phaco consumables); cochlear-implant programming and audiology engineering in tertiary ENT centres and under the ADIP scheme.
• Orthopaedic and dental implants: Indian manufacturers of trauma plates, nails and joint systems; machining, coating (HA/plasma spray), sterilisation validation, and NPPA-capped pricing compliance for knee systems.
• Hospital-side roles: cardiac perfusionist and ECMO technologist (oxygenator and circuit management), cath-lab and CTVS biomedical engineers, implant inventory and traceability under NABH.
• Regulatory, quality and clinical affairs: CDSCO licensing (MD-7/MD-9, MD-14/MD-15), ISO 13485 and ISO 14971 files, ISO 10993 biological evaluation dossiers, MvPI adverse-event reporting, notified-body and NABL test-lab work.
• Research and public programmes: SCTIMST and ICMR device programmes, IIT Madras LVAD work, DBT/BIRAC-funded medical-device incubators and the AMTZ cluster at Visakhapatnam.

Interview questions

• Q: When would you choose a mechanical over a bioprosthetic heart valve? A: For younger patients with long life expectancy who can manage reliable anticoagulation; a tissue valve suits older patients, planned pregnancy or high bleeding risk because it avoids lifelong warfarin.
• Q: What does DDD mean in the pacemaker code? A: Both chambers paced, both sensed, and dual response — pacing can be inhibited or triggered depending on the sensed event.
• Q: Why do small-diameter synthetic vascular grafts fail? A: Low flow and low shear plus a thrombogenic non-endothelialised surface cause thrombosis, and anastomotic intimal hyperplasia narrows the lumen; autologous vein performs far better.
• Q: What is stress shielding and why does it matter in hip implants? A: A stiff metallic stem carries load that bone used to carry, so the unloaded bone resorbs per Wolff's law, weakening fixation; lower-modulus titanium and better load-sharing geometry reduce it.
• Q: Why is drug elution used on a coronary stent? A: The antiproliferative drug (sirolimus, everolimus, paclitaxel) suppresses smooth-muscle proliferation that causes in-stent restenosis, cutting restenosis several-fold compared with bare metal.
• Q: Which Indian regulation governs an implant, and what licence does a Class D implant need? A: The Medical Devices Rules, 2017 under the Drugs and Cosmetics Act, 1940; a Class C/D manufacturer needs CDSCO licence MD-7/MD-9 with an ISO 13485 quality system, imports need MD-14/MD-15.
• Q: What is EOA and why not just quote the geometric orifice area? A: Effective orifice area is the hydraulically useful area derived from flow and pressure drop; flow contraction and viscous loss make it smaller than the geometric area, so EOA predicts the patient's gradient.
• Q: Why does an LVAD patient bleed from the gut? A: The pump's high shear cleaves von Willebrand factor multimers (acquired von Willebrand syndrome), and continuous non-pulsatile flow promotes arteriovenous malformations; both combine with mandatory anticoagulation.
• Q: What limits how long a microporous membrane oxygenator can run? A: Plasma leakage through wetted micropores, protein deposition and clot in the fibre bundle degrade gas transfer; polymethylpentene diffusion membranes avoid plasma leak and are used for long ECMO runs.
• Q: What makes a dental or cementless orthopaedic implant succeed? A: Osseointegration — primary mechanical stability, roughened or HA-coated titanium surface, atraumatic low-temperature drilling, and micromotion kept small during healing.
• Q: Is an implant with metal parts safe in MRI? A: It depends on labelling — MR safe, MR conditional (safe within stated field, gradient and SAR limits) or MR unsafe; risks are heating, force and torque, device malfunction and image artefact.
• Q: Tricky — a pacemaker's battery is 1 Ah and pacing drain is only ~2 µA, so why does it not last 50 years? A: Quiescent circuit, sensing, telemetry and diagnostics dominate the drain, lead impedance and output settings change with time, and a replacement reserve is designed in — giving roughly 8-12 years.

Common mistakes

• Treating all implants as the same regulatory object — class (A-D), licensing authority and standards differ sharply between a Class A dressing and a Class D valve.
• Mixing up mechanical and bioprosthetic valve properties, especially claiming tissue valves need lifelong warfarin or that mechanical valves degenerate by calcification.
• Using geometric orifice area in the Gorlin/ISO 5840 formula, or putting Q in L/min instead of mL/s so the EOA comes out about 17 times too small (1 L/min = 16.7 mL/s).
• Ignoring the quiescent current when computing pacemaker longevity, and omitting the replacement reserve.
• Forgetting that joint-implant life is limited by the biological reaction to wear debris, not by the liner wearing through.
• Quoting withdrawn IS numbers or old NPPA stent/knee price ceilings — the ceilings are revised periodically, so cite the current notification.
• Saying a thinner or stiffer implant is simply better — radial strength, fatigue life, deliverability and host response trade off against each other.

Related topics

Biomaterials and biocompatibility · Biomechanics and kinesiology · Medical device design and development · Tissue engineering basics · Renal physiology and dialysis · Rehabilitation engineering and assistive devices